tfx-20230702

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


(Mark One)
☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 2, 2023


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number 1-5353

TELEFLEX INCORPORATED

(Exact name of registrant as specified in its charter)


Delaware						23-1147939
(State or other jurisdiction of incorporation or organization)						(I.R.S. employer identification no.)

550 E. Swedesford Rd., Suite 400 Wayne, PA 19087

(Address of principal executive offices and zip code)

(610) 225-6800

(Registrant’s telephone number, including area code)

(None)

(Former Name, Former Address and Former Fiscal Year,

If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $1.00 per share

TFX

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The registrant had 46,992,159 shares of common stock, par value $1.00 per share, outstanding as of August 1, 2023 .

TELEFLEX INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED JULY 2, 2023

TABLE OF CONTENTS

Page

PART I — FINANCIAL INFORMATION

Item 1:

Financial Statements (Unaudited):

Condensed Consolidated Statements of Income

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Changes in Equity

Notes to Condensed Consolidated Financial Statements

Item 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3:

Quantitative and Qualitative Disclosures About Market Risk

Item 4:

Controls and Procedures

PART II — OTHER INFORMATION

Item 1:

Legal Proceedings

Item 1A:

Risk Factors

Item 2:

Unregistered Sales of Equity Securities and Use of Proceeds

Item 3:

Defaults Upon Senior Securities

Item 4:

Mine Safety Disclosures

Item 5:

Other Information

Item 6:

Exhibits

SIGNATURES

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
	(Dollars and shares in thousands, except per share)
Net revenues	$	743,259	$	704,542	$	1,454,191	$	1,346,257
Cost of goods sold	335,436		315,709		654,988		611,191
Gross profit	407,823		388,833		799,203		735,066
Selling, general and administrative expenses	223,306		216,825		456,022		420,757
Research and development expenses	39,448		36,934		80,917		73,294
Restructuring and impairment charges (credits)	1,508		(83)		3,729		2,322

Income from continuing operations before interest and taxes	143,561		135,157		258,535		238,693
Interest expense	17,762		11,419		36,099		21,837
Interest income	(1,156)		(229)		(1,999)		(451)

Income from continuing operations before taxes	126,955		123,967		224,435		217,307
Taxes on income from continuing operations	15,532		18,412		35,716		34,385
Income from continuing operations	111,423		105,555		188,719		182,922
Operating loss from discontinued operations	(114)		(54)		(825)		(348)
Tax benefit on operating loss from discontinued operations	(26)		(13)		(189)		(81)
Loss from discontinued operations	(88)		(41)		(636)		(267)
Net income	$	111,335	$	105,514	$	188,083	$	182,655
Earnings per share:
Basic:
Income from continuing operations	$	2.37	$	2.25	$	4.02	$	3.90
Loss from discontinued operations	—		—		(0.02)		—
Net income	$	2.37	$	2.25	$	4.00	$	3.90
Diluted:
Income from continuing operations	$	2.35	$	2.23	$	3.99	$	3.86
Loss from discontinued operations	—		—		(0.01)		—
Net income	$	2.35	$	2.23	$	3.98	$	3.86
Weighted average common shares outstanding
Basic	46,981		46,901		46,965		46,889
Diluted	47,329		47,347		47,307		47,374

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
	(Dollars in thousands)
Net income	$	111,335	$	105,514	$	188,083	$	182,655
Other comprehensive (loss) income, net of tax:
Foreign currency translation, net of tax of $1,263, $(6,688), $4,233, and $(7,823) for the three and six months periods, respectively	(2,521)		(45,053)		16,049		(68,382)
Pension and other postretirement benefit plans adjustment, net of tax of $(352), $(647), $(706), and $(1,146) for the three and six months periods, respectively	1,195		2,026		2,408		3,612
Derivatives qualifying as hedges, net of tax of $330, $(104), $450, and $(134) for the three and six months periods, respectively	793		2,577		3,201		3,034
Other comprehensive (loss) income, net of tax:	(533)		(40,450)		21,658		(61,736)
Comprehensive income	$	110,802	$	65,064	$	209,741	$	120,919

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	July 2, 2023		December 31, 2022
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	250,816	$	292,034
Accounts receivable, net	429,309		408,834
Inventories	631,555		578,507
Prepaid expenses and other current assets	120,190		125,084
Prepaid taxes	13,929		6,524

Total current assets	1,445,799		1,410,983
Property, plant and equipment, net	464,609		447,205
Operating lease assets	123,215		131,211
Goodwill	2,546,130		2,536,730
Intangible assets, net	2,227,947		2,306,165
Deferred tax assets	6,278		6,402
Other assets	81,747		89,367

Total assets	$	6,895,725	$	6,928,063
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	87,500	$	87,500
Accounts payable	142,081		126,807
Accrued expenses	127,861		140,644

Payroll and benefit-related liabilities	106,177		133,092
Accrued interest	5,793		5,332
Income taxes payable	20,184		24,736
Other current liabilities	65,853		63,381

Total current liabilities	555,449		581,492
Long-term borrowings	1,470,674		1,624,023
Deferred tax liabilities	385,113		388,886
Pension and postretirement benefit liabilities	30,686		31,394
Noncurrent liability for uncertain tax positions	6,534		5,805

Noncurrent operating lease liabilities	112,229		120,437
Other liabilities	119,948		154,058
Total liabilities	2,680,633		2,906,095
Commitments and contingencies
Total shareholders' equity	4,215,092		4,021,968
Total liabilities and shareholders' equity	$	6,895,725	$	6,928,063

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Six Months Ended
	July 2, 2023		June 26, 2022
	(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net income	$	188,083	$	182,655
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	636		267
Depreciation expense	36,723		33,499
Intangible asset amortization expense	83,600		81,137
Deferred financing costs and debt discount amortization expense	1,700		2,103



Changes in contingent consideration	(6,776)		145
Assets impairment charges	—		1,497
Stock-based compensation	14,020		12,801

Deferred income taxes, net	460		937
Payments for contingent consideration	—		(2,722)
Interest benefit on swaps designated as net investment hedges	(10,288)		(10,145)
Other	2,824		(1,779)
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(16,587)		(43,939)
Inventories	(45,630)		(48,682)
Prepaid expenses and other assets	12,120		15,464
Accounts payable, accrued expenses and other liabilities	(53,766)		(38,722)
Income taxes receivable and payable, net	(36,501)		(82,657)
Net cash provided by operating activities from continuing operations	170,618		101,859
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(39,374)		(32,445)
Proceeds from sale of business and assets	—		530
Payments for businesses and intangibles acquired, net of cash acquired	(129)		(22,971)

Net interest proceeds on swaps designated as net investment hedges	10,275		10,314


Net cash used in investing activities from continuing operations	(29,228)		(44,572)
Cash flows from financing activities of continuing operations:

Reduction in borrowings	(154,500)		(135,500)

Net payments from share based compensation plans and related tax impacts	572		(4,366)
Payments for contingent consideration	(121)		(3,012)
Dividends paid	(31,941)		(31,892)

Net cash used in financing activities from continuing operations	(185,990)		(174,770)
Cash flows from discontinued operations:
Net cash used in operating activities	(454)		(280)
Net cash used in discontinued operations	(454)		(280)
Effect of exchange rate changes on cash and cash equivalents	3,836		(19,200)
Net decrease in cash and cash equivalents	(41,218)		(136,963)
Cash and cash equivalents at the beginning of the period	292,034		445,084
Cash and cash equivalents at the end of the period	$	250,816	$	308,121

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)


	Common Stock			Additional Paid In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock			Total
	Shares	Dollars								Shares	Dollars
	(Dollars and shares in thousands, except per share)
Balance at December 31, 2022	47,957	$	47,957	$	715,118	$	3,817,304	$	(403,522)	1,032	$	(154,889)	$	4,021,968

Net income						76,748							76,748
Cash dividends ($0.34 per share)						(15,969)							(15,969)
Other comprehensive income								22,191					22,191
Shares issued under compensation plans	18	18		2,333						(19)	2,639		4,990
Deferred compensation	—	—		324						(6)	1		325
Balance at April 2, 2023	47,975	47,975		717,775		3,878,083		(381,331)		1,007	(152,249)		4,110,253
Net income						111,335							111,335
Cash dividends ($0.34 per share)						(15,972)							(15,972)
Other comprehensive income								(533)					(533)
Shares issued under compensation plans	23	23		9,920						—	66		10,009

Balance at July 2, 2023	47,998	$	47,998	$	727,695	$	3,973,446	$	(381,864)	1,007	$	(152,183)	$	4,215,092


	Common Stock			Additional Paid In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock			Total
	Shares	Dollars								Shares	Dollars
	(Dollars and shares in thousands, except per share)
Balance at December 31, 2021	47,929	$	47,929	$	693,090	$	3,517,954	$	(346,959)	1,069	$	(157,266)	$	3,754,748

Net income						77,141							77,141
Cash dividends ($0.34 per share)						(15,946)							(15,946)
Other comprehensive loss								(21,286)					(21,286)
Shares issued under compensation plans	5	5		(950)						(27)	894		(51)
Deferred compensation	—	—		100						(5)	828		928
Balance at March 27, 2022	47,934	47,934		692,240		3,579,149		(368,245)		1,037	(155,544)		3,795,534
Net income						105,514							105,514
Cash dividends ($0.34 per share)						(15,946)							(15,946)
Other comprehensive income								(40,450)					(40,450)
Shares issued under compensation plans	6	6		7,918						(2)	151		8,075
Deferred compensation	—	—		(2)						—	5		3
Balance at June 26, 2022	47,940	$	47,940	$	700,156	$	3,668,717	$	(408,695)	1,035	$	(155,388)	$	3,852,730

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(all tabular amounts in thousands unless otherwise noted)

Note 1 — Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements.

In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Note 2 — Recently issued accounting standards

From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.

Note 3 — Net revenues

We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For our Original Equipment and Development Services ("OEM") segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which constituted 87%, 11% and 2% of consolidated net revenues, respectively, for the six months ended July 2, 2023. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table disaggregates revenue by global product category for the three and six months ended July 2, 2023 and June 26, 2022.


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
Vascular access	$	173,785	$	163,907	$	351,437	$	330,041
Anesthesia	100,842		104,695		194,174		191,652
Interventional	124,780		114,342		241,677		211,201
Surgical	105,953		99,642		204,976		189,344
Interventional urology	77,819		79,818		153,197		154,713
OEM	84,128		70,003		161,125		127,659
Other (1)	75,952		72,135		147,605		141,647
Net revenues (2)	$	743,259	$	704,542	$	1,454,191	$	1,346,257

(1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products).

(2) The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments includes net revenues from each of the non-OEM product categories listed above.

Note 4 — Acquisitions and Divestiture

Acquisition

In the fourth quarter of 2022, we completed the acquisition of Standard Bariatrics, Inc. (“Standard Bariatrics”), a privately-held medical device company that commercialized a powered stapling technology for bariatric surgery that complements our surgical product portfolio. Under the terms of the agreement, we acquired Standard Bariatrics for cash payments of $173 million, with the potential to make three milestone payments up to $130 million in the aggregate if certain commercial milestones are met.

Divestiture

On May 15, 2021, we entered into a definitive agreement to sell certain product lines within our global respiratory product portfolio (the "Divested respiratory business") to Medline Industries, Inc. (“Medline”) for consideration of $286.0 million, reduced by $12 million in working capital not transferring to Medline, which is subject to customary post close adjustments (the "Respiratory business divestiture"). In connection with the Respiratory business divestiture, we also entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services, including a manufacturing and supply transition agreement (the "MSTA").

On June 28, 2021, the first day of the third quarter of 2021, we completed the initial phase of the Respiratory business divestiture, pursuant to which we received cash proceeds of $259 million. The second phase of the Respiratory business divestiture will occur once we transfer certain additional manufacturing assets to Medline and is expected to occur prior to the end of 2023. We plan to recognize the remaining consideration, and any gain on sale resulting from the completion of the second phase of the divestiture, when it becomes realizable.

Net revenues attributed to services provided to Medline in accordance with the MSTA, which are presented within our Americas reporting segment, were $20.9 million and $40.9 million for the three and six months ended July 2, 2023, respectively, and $20.3 million and $41.4 million for the three and six months ended June 26, 2022, respectively.

Subsequent event

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

the agreement, we will acquire Palette for an initial cash payment of $600 million, with additional consideration of up to $50 million payable upon the achievement of certain commercial milestones. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed in the fourth quarter of 2023. We anticipate using borrowings under our revolving credit facility and cash on hand to finance the acquisition.

Note 5 — Restructuring and impairment charges

Respiratory divestiture plan

During 2021, in connection with the Respiratory business divestiture, we committed to a restructuring plan designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites being transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan:


			Total estimated amount expected to be incurred
Plan expense estimates:			(Dollars in millions)
Restructuring charges (1)			$5 million to $8 million
Restructuring related charges (2)			$19 million to $22 million
Total restructuring and restructuring related charges			$24 million to $30 million

(1) Substantially all of the charges consist of employee termination benefit costs.

(2)Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold.

We recorded restructuring related charges with respect to the Respiratory divestiture plan of $2.0 million and $4.1 million for the three and six months ended July 2, 2023, respectively, and $2.4 million and $4.4 million for the three and six months ended June 26, 2022, respectively. The restructuring related charges were included within cost of goods sold.

As of July 2, 2023, we have incurred net aggregate restructuring expenses related to the Respiratory divestiture plan of $3.5 million. Additionally, as of July 2, 2023, we have incurred net aggregate restructuring related charges in connection with the Respiratory divestiture plan of $16.3 million, which were primarily included in cost of goods sold. As of July 2, 2023, we have a restructuring reserve of $3.5 million in connection with this plan.

2022 Restructuring plan

In November 2022, we initiated a strategic restructuring plan designed to improve operating performance and position the organization to deliver long-term durable growth by creating efficiencies that align with our high growth strategic objectives (the “2022 Restructuring plan”). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial.

Restructuring and impairment charges recognized for the three and six months ended July 2, 2023 and June 26, 2022 consisted of the following:


Three Months Ended July 2, 2023
	Termination Benefits		Other Costs (1)		Total
2022 Restructuring plan	$	984	$	138	$	1,122
Respiratory divestiture plan	127		—		127


Other restructuring programs (2)	73		186		259
Restructuring charges	$	1,184	$	324	$	1,508

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)


Three Months Ended June 26, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	129	$	31	$	160

2019 Footprint realignment plan	(400)		21		(379)
2018 Footprint realignment plan	153		233		386
Other restructuring programs (3)	(406)		156		(250)
Restructuring charges	$	(524)	$	441	$	(83)


Six Months Ended July 2, 2023
	Termination Benefits		Other Costs (1)		Total
2022 Restructuring plan	$	3,117	$	211	$	3,328

Respiratory divestiture plan	255		12		267

Other restructuring programs (2)	(241)		375		134
Restructuring charges	$	3,131	$	598	$	3,729


Six Months Ended June 26, 2022
	Termination Benefits		Other Costs (1)		Total
Respiratory divestiture plan	$	235	$	45	$	280

2019 Footprint realignment plan	(1,070)		45		(1,025)
2018 Footprint realignment plan	311		295		606
Other restructuring programs (3)	726		238		964
Restructuring charges	202		623		825
Asset impairment charges	—		1,497		1,497
Restructuring and impairment charges	$	202	$	2,120	$	2,322

(1) Other costs include facility closure, contract termination and other exit costs.

(2) Includes activity primarily related to our 2014, 2018, and 2019 Footprint realignment plans.

(3) Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities, the 2021 Restructuring plan and the 2014 Footprint realignment plan.

Note 6 — Inventories

Inventories as of July 2, 2023 and December 31, 2022 consisted of the following:


	July 2, 2023		December 31, 2022
Raw materials	$	202,251	$	186,641
Work-in-process	107,258		98,993
Finished goods	322,046		292,873
Inventories	$	631,555	$	578,507

Note 7 — Goodwill and other intangible assets

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the six months ended July 2, 2023:


	Americas		EMEA		Asia		OEM		Total
December 31, 2022	$	1,731,093	$	468,524	$	225,103	$	112,010	$	2,536,730




Currency translation adjustment	3,186		10,151		(3,937)		—		9,400
July 2, 2023	$	1,734,279	$	478,675	$	221,166	$	112,010	$	2,546,130

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The gross carrying amount of, and accumulated amortization relating to, intangible assets as of July 2, 2023 and December 31, 2022 were as follows:


	Gross Carrying Amount				Accumulated Amortization
	July 2, 2023		December 31, 2022		July 2, 2023		December 31, 2022
Customer relationships	$	1,331,398	$	1,328,539	$	(529,684)	$	(497,335)
In-process research and development	27,517		27,075		—		—
Intellectual property	1,602,296		1,599,355		(693,064)		(646,643)
Distribution rights	23,245		23,115		(21,605)		(21,090)
Trade names	565,716		564,023		(77,959)		(71,128)
Non-compete agreements	21,981		21,429		(21,894)		(21,175)
	$	3,572,153	$	3,563,536	$	(1,344,206)	$	(1,257,371)

Note 8 — Financial instruments

Foreign currency forward contracts

We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with our currency translation exposures, which generally approximate one month. For the three and six months ended July 2, 2023, we recognized gains of $2.0 million and $2.1 million, respectively, related to non-designated foreign currency forward contracts. For the three and six months ended June 26, 2022, we recognized a gain of $0.1 million and a loss of $3.2 million related to non-designated foreign currency forward contracts.

The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of July 2, 2023 and December 31, 2022 was $222.3 million and $184.8 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of July 2, 2023 and December 31, 2022 was $137.1 million and $152.9 million, respectively. All open foreign currency forward contracts as of July 2, 2023 have durations of 12 months or less.

Cross-currency interest rate swaps

During 2019, we entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $250 million at an annual interest rate of 4.875% for €219.2 million at an annual interest rate of 2.4595%. The swap agreements are designed as net investment hedges and expire on March 4, 2024.

During 2018, we entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements are designed as net investment hedges and expire on October 4, 2023.

The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement.

The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI"). The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the three and six months ended July 2, 2023 and June 26, 2022:

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
Foreign exchange (loss) gain	$	(4,259)	$	22,614	$	(14,290)	$	26,454
Interest benefit	5,180		5,297		10,288		10,145

Balance sheet presentation

The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of July 2, 2023 and December 31, 2022:


	July 2, 2023		December 31, 2022
	Fair Value
Asset derivatives:
Designated foreign currency forward contracts	$	7,230	$	3,154
Non-designated foreign currency forward contracts	145		41
Cross-currency interest rate swaps	41,906		48,503
Prepaid expenses and other current assets	49,281		51,698
Cross-currency interest rate swaps	—		11,912
Other assets	—		11,912
Total asset derivatives	$	49,281	$	63,610
Liability derivatives:
Designated foreign currency forward contracts	$	3,162	$	983
Non-designated foreign currency forward contracts	249		477
Other current liabilities	3,411		1,460


Total liability derivatives	$	3,411	$	1,460

See Note 10 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. There was no ineffectiveness related to our cash flow hedges during the three and six months ended July 2, 2023 and June 26, 2022.

Trade receivables

The allowance for credit losses as of July 2, 2023 and December 31, 2022 was $9.5 million and $8.6 million, respectively. The current portion of the allowance for credit losses, which was $5.5 million and $4.9 million as of July 2, 2023 and December 31, 2022, respectively, was recognized as a reduction of accounts receivable, net.

Note 9 — Fair value measurement

The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of July 2, 2023 and December 31, 2022:


	Total carrying value at July 2, 2023		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	12,211	$	12,211	$	—	$	—
Derivative assets	49,281		—		49,281		—
Derivative liabilities	3,411		—		3,411		—
Contingent consideration liabilities	37,125		—		—		37,125

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)


	Total carrying value at December 31, 2022		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	$	10,097	$	10,097	$	—	$	—
Derivative assets	63,610		—		63,610		—
Derivative liabilities	1,460		—		1,460		—
Contingent consideration liabilities	44,022		—		—		44,022

Valuation Techniques

Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under our benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices.

Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forwards and cross-currency interest rate swaps to manage foreign currency transaction exposure, as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forwards and cross-currency swaps by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties.

Our financial liabilities valued based upon Level 3 inputs (inputs that are not observable in the market) are comprised of contingent consideration arrangements pertaining to our acquisitions.

Contingent consideration

Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates.

We determine the fair value of certain contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn-out period using management's best estimates) or discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect.

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities.

Contingent Consideration Liability

Valuation Technique

Unobservable Input

Revenue-based

Monte Carlo simulation

Revenue volatility

31.4

Risk free rate

Cost of debt structure

Projected year of payment

2024 - 2026

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table provides information regarding changes in our contingent consideration liabilities for the three and six months ended July 2, 2023:



	Contingent consideration
Balance – December 31, 2022	$	44,022
Payments	(121)
Revaluations	(6,776)

Balance – July 2, 2023	$	37,125

Note 10 — Shareholders' equity

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:


	Three Months Ended		Six Months Ended
	July 2, 2023	June 26, 2022	July 2, 2023	June 26, 2022
Basic	46,981	46,901	46,965	46,889
Dilutive effect of share-based awards	348	446	342	485

Diluted	47,329	47,347	47,307	47,374

The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.7 million for the three and six months ended July 2, 2023, and 0.4 million and 0.3 million for the three and six months ended June 26, 2022, respectively.

The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the six months ended July 2, 2023 and June 26, 2022:


	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2022	$	4,931	$	(135,799)	$	(272,654)	$	(403,522)
Other comprehensive income (loss) before reclassifications	8,056		(388)		16,049		23,717
Amounts reclassified from accumulated other comprehensive income	(4,855)		2,796		—		(2,059)
Net current-period other comprehensive income	3,201		2,408		16,049		21,658

Balance as of July 2, 2023	$	8,132	$	(133,391)	$	(256,605)	$	(381,864)


	Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2021	$	1,081	$	(138,290)	$	(209,750)	$	(346,959)
Other comprehensive income (loss) before reclassifications	2,839		939		(68,382)		(64,604)
Amounts reclassified from accumulated other comprehensive income	195		2,673		—		2,868
Net current-period other comprehensive income (loss)	3,034		3,612		(68,382)		(61,736)

Balance as of June 26, 2022	$	4,115	$	(134,678)	$	(278,132)	$	(408,695)

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into (income) expense, net of tax, for the three and six months ended July 2, 2023 and June 26, 2022:


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
(Gains) Loss on foreign exchange contracts:
Cost of goods sold	$	(2,181)	$	(229)	$	(5,235)	$	169
Total before tax	(2,181)		(229)		(5,235)		169
Taxes	178		24		380		26
Net of tax	(2,003)		(205)		(4,855)		195
Amortization of pension and other postretirement benefit items (1):
Actuarial losses	2,069		1,989		4,135		3,989
Prior-service costs	(252)		(252)		(504)		(504)

Total before tax	1,817		1,737		3,631		3,485
Tax benefit	(418)		(405)		(835)		(812)
Net of tax	1,399		1,332		2,796		2,673
Total reclassifications, net of tax	$	(604)	$	1,127	$	(2,059)	$	2,868

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

Note 11 — Taxes on income from continuing operations

Three Months Ended

Six Months Ended

July 2, 2023

June 26, 2022

July 2, 2023

June 26, 2022

Effective income tax rate

12.2%

14.9%

15.9%

15.8%

The effective income tax rates for the three and six months ended July 2, 2023 were 12.2% and 15.9%, respectively. The effective income tax rate for the three and six months ended July 2, 2023 reflects the tax impact of a non-taxable contingent consideration adjustment recognized in connection with a decrease in the estimated fair value of our contingent consideration liabilities. The effective income tax rate for the six months ended July 2, 2023 reflects an increase in tax expense related to the revaluation of certain U.S. state operating losses and credit carryforwards. The effective income tax rates for all periods reflect a tax benefit from research and development credits and a net-tax benefit related to share-based compensation.

Note 12 — Commitments and contingent liabilities

Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At July 2, 2023, we have recorded $2.5 million and $3.6 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of July 2, 2023. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of July 2, 2023, we have recorded accrued liabilities of $0.6 million in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters.

Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.

Other: In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty exists related to the enforceability of and implementation process for the payback law. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, which appeals remain pending. As of July 2, 2023, our reserve for this matter was $12.6 million, of which, $1.5 million was recorded as a reduction of revenue in 2023. If the payback was to ultimately be enforced in its existing form, we estimate that we would be required to remit payments in excess of our current reserve of up to $18.6 million.

On April 4, 2023, one of our Mexican subsidiaries received a notification from the Mexican Federal Tax Administration Service (“SAT”) setting forth its preliminary findings with respect to a foreign trade operations audit carried out by SAT for the period from July 1, 2017 to June 6, 2019. The preliminary findings stated that our Mexican subsidiary did not evidence the export of goods temporarily imported under Mexico’s Manufacturing, Maquila and Export Services Industries Program (“IMMEX Program”), therefore triggering the potential obligation for payment of import duties, value added tax, customs processing fees and other fines and penalties. In response to the notification, our Mexican subsidiary has requested that the matter be referred to the Procuraduría de la Defensa del Contribuyente, or “PRODECON,” (local tax ombudsperson) to help facilitate the process. In June, SAT was provided with the appropriate documentation evidencing the export of the goods in accordance with the requirements of the IMMEX Program.

While we cannot predict with certainty the outcome of this audit, based on currently known information, we do not believe a loss is either probable or estimable. Accordingly, no loss contingency has been recorded in our financial statements as of July 2, 2023 related to this matter. However, if the final resolution of the matter is not favorable to us, our Mexican subsidiary may be required to make payment of certain import duties, fines and surcharges, which could be material.

Tax audits and examinations: We are routinely subject to tax examinations by various tax authorities. As of July 2, 2023, the most significant tax examinations in process were in Ireland and Germany. We may establish reserves with respect to our uncertain tax positions, after we adjust the reserves to address developments with respect to our uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to our recorded tax liabilities, which could impact our financial results.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 13 — Segment information

The following tables present our segment results for the three and six months ended July 2, 2023 and June 26, 2022:


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
Americas	$	424,644	$	412,740	$	836,508	$	790,701
EMEA	147,809		145,190		291,149		282,098
Asia	86,678		76,609		165,409		145,799
OEM	84,128		70,003		161,125		127,659
Net revenues	$	743,259	$	704,542	$	1,454,191	$	1,346,257


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
Americas	$	116,303	$	114,467	$	214,921	$	211,368
EMEA	13,097		12,725		25,868		21,819
Asia	23,148		21,494		44,148		38,911
OEM	23,779		17,836		43,816		28,759
Total segment operating profit (1)	176,327		166,522		328,753		300,857
Unallocated expenses (2)	(32,766)		(31,365)		(70,218)		(62,164)
Income from continuing operations before interest and taxes	$	143,561	$	135,157	$	258,535	$	238,693

(1)Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.

(2)Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances and restructuring and impairment charges.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Teleflex Incorporated (“we,” “us,” “our" and “Teleflex”) is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.

We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, particularly in Asia, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.

In May 2023, our Board of Directors approved the termination of the Teleflex Incorporated Retirement Income Plan (the “TRIP”), a U.S. defined benefit plan, effective as of August 1, 2023. The TRIP is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and is intended to be tax-qualified under Section 401(a) of the Internal Revenue Code of 1986, as amended (“Code”). Participation in and accrual of benefits under the TRIP have been frozen since 2012, and, as of July 2, 2023, the TRIP assets exceeded the liabilities. In June 2023, we notified participants of our intent to terminate the TRIP and requested a determination letter from the Internal Revenue Services (“IRS”) stating that the TRIP satisfies the requirements, in form, to be tax-qualified under Code Section 401(a) upon termination. Because the TRIP is an ERISA plan, the termination is subject to approval by the Pension Benefit Guaranty Corporation (“PBGC”). While we expect to proceed with the termination, we may decide not to proceed for certain reasons including, for example, if the cost to terminate the TRIP exceeds our current expectations. Should we proceed with the termination, participants will receive their full accrued benefits from TRIP assets, and we plan to offer participants who have not started their TRIP benefits an opportunity to elect to receive their benefits in the form of a lump sum distribution or to commence their benefits in the form of monthly annuity payments in connection with the termination of the TRIP. After the termination has been approved by the PBGC, one or more annuity contracts with a qualifying insurer(s) will be purchased to provide TRIP benefits that have not already been distributed.

Upon settlement of the TRIP we are required to remeasure the plan assets and obligation and will recognize a settlement loss for the recognition of the unrecognized losses in accumulated other comprehensive income including the effects of the remeasurement. As of July 2, 2023, the pre-tax accumulated other comprehensive loss related to the TRIP was approximately $200 million. We expect to recognize a portion of the settlement charge during the fourth quarter of 2023, when eligible participants who elect the lump sum option receive their payments, and we expect to recognize the remainder of the settlement charge upon annuitization of the TRIP benefits, which we expect to occur during 2024.

Subsequent event

On July 25, 2023, we executed a definitive agreement to acquire Palette Life Sciences AB (“Palette”), a privately held medical device company that sells a portfolio of hyaluronic acid gel-based products primarily utilized in the treatment of urology diseases including a rectal spacing product used in connection with radiation therapy treatment of prostate cancer. The acquisition will complement our interventional urology product portfolio. Under the terms of the agreement, we will acquire Palette for an initial cash payment of $600 million, with additional consideration of up to $50 million payable upon the achievement of certain commercial milestones. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed in the fourth quarter of 2023. We anticipate using borrowings under our revolving credit facility and cash on hand to finance the acquisition.

Results of Operations

As used in this discussion, "new products" are products for which commercial sales have commenced within the past 36 months, and “existing products” are products for which commercial sales commenced more than 36 months ago. Discussion of results of operations items that reference the effect of one or more acquired and/or divested businesses or assets (except as noted below with respect to acquired distributors) generally reflects the impact of the acquisitions and/or divestitures within the first 12 months following the date of the acquisition and/or divestiture. In addition to increases and decreases in the per unit selling prices of our products to our customers, our discussion of the impact of product price increases and decreases also reflects the impact on the pricing of our products resulting from the elimination of the distributor, either through acquisition or termination of the distributor, from the sales channel. All of the dollar amounts in the tables are presented in millions unless otherwise noted.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Net revenues


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
Net revenues	$	743.3	$	704.5	$	1,454.2	$	1,346.3

Net revenues for the three months ended July 2, 2023 increased $38.8 million, or 5.5%, compared to the prior year period, primarily due to a $49.1 million increase in sales of new products and price increases, partially offset by a $31.3 million decrease in sales volume of existing products.

Net revenues for the six months ended July 2, 2023 increased $107.9 million, or 8.0%, compared to the prior year period, primarily due to a $112.1 million increase in sales of new products and price increases. The increase in net revenues was partially offset by a $28.2 million decrease in sales volume of existing products, notwithstanding the impact of a five-day increase in the number of shipping days during the six months ended July 2, 2023 and, to a lesser extent, unfavorable fluctuations in foreign currency exchange rates.

Gross profit


	Three Months Ended						Six Months Ended
	July 2, 2023			June 26, 2022			July 2, 2023			June 26, 2022
Gross profit	$	407.8		$	388.8		$	799.2		$	735.1
Percentage of sales	54.9		%	55.2		%	55.0		%	54.6		%

Gross margin for the three months ended July 2, 2023 decreased 30 basis points, or 0.5%, compared to the prior year period, primarily due to continued cost inflation from macro-economic factors, specifically, raw materials and labor costs, an increase in costs associated with product recalls and quality issues and an unfavorable impact on manufacturing productivity due to raw material supply. The decrease in gross profit was partially offset by price increases, lower logistics and distribution related costs and benefits from cost improvement initiatives.

Gross margin for the six months ended July 2, 2023 increased 40 basis points, or 0.7%, compared to the prior year period, primarily due to price increases, lower logistics and distribution related costs and benefits from cost improvement initiatives, partially offset by continued cost inflation from macro-economic factors, specifically, raw materials, an increase in costs associated with product recalls and quality issues and an unfavorable impact on manufacturing productivity due to raw material supply.

financial statements as of July 2, 2023 related to this matter. However, if the final resolution of the matter is not favorable to us, our Mexican subsidiary may be required to make payment of certain import duties, fines and surcharges, which could be material.

Selling, general and administrative


	Three Months Ended						Six Months Ended
	July 2, 2023			June 26, 2022			July 2, 2023			June 26, 2022
Selling, general and administrative	$	223.3		$	216.8		$	456.0		$	420.8
Percentage of sales	30.0		%	30.8		%	31.4		%	31.3		%

Selling, general and administrative expenses for the three months ended July 2, 2023 increased $6.5 million, compared to the prior year period primarily due to higher sales expenses across certain of our product portfolios, higher operating expenses incurred by acquired businesses, primarily Standard Bariatrics and higher IT related costs, partially offset by a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities.

Selling, general and administrative expenses for the six months ended July 2, 2023 increased $35.2 million, compared to the prior year period primarily due to higher sales and marketing expenses across certain of our product portfolios, higher operating expenses incurred by acquired businesses, primarily Standard Bariatrics and higher IT related costs. The increases in selling, general and administrative expenses were partially offset by favorable fluctuations in foreign currency exchange rates and a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities.

Research and development


	Three Months Ended						Six Months Ended
	July 2, 2023			June 26, 2022			July 2, 2023			June 26, 2022
Research and development	$	39.4		$	36.9		$	80.9		$	73.3
Percentage of sales	5.3		%	5.2		%	5.6		%	5.4		%

The increases in research and development expenses for the three and six months ended July 2, 2023 compared to the prior year period were primarily attributable to higher project spend within certain of our product portfolios and expenses incurred by Standard Bariatrics, partially offset by lower expenses related to the European Union Medical Device Regulation related costs.

Restructuring and impairment charges (credits)


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
Restructuring and impairment charges (credits)	$	1.5	$	(0.1)	$	3.7	$	2.3

Restructuring charges for the three and six months ended July 2, 2023 primarily consisted of termination benefits related to the 2022 Restructuring plan (defined below).

2022 Restructuring plan

Respiratory divestiture plan

We have an ongoing restructuring plan, initiated in connection with the Respiratory business divestiture, designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex (the “Respiratory divestiture plan”). We estimate that we will incur aggregate pre-tax restructuring charges in connection with the Respiratory divestiture plan of $24 million to $30 million.

For additional information regarding our restructuring plans, refer to Note 5 within the condensed consolidated financial statements included in this report.

Interest expense


	Three Months Ended						Six Months Ended
	July 2, 2023			June 26, 2022			July 2, 2023			June 26, 2022
Interest expense	$	17.8		$	11.4		$	36.1		$	21.8
Average interest rate on debt	4.1		%	2.3		%	4.0		%	2.2		%

The increases in interest expense for the three and six months ended July 2, 2023 compared to the prior year period were primarily due to higher average interest rates resulting from increases in interest rates associated with our variable interest rate debt instruments partially offset by a decrease in average debt outstanding.

Taxes on income from continuing operations


	Three Months Ended				Six Months Ended
	July 2, 2023		June 26, 2022		July 2, 2023		June 26, 2022
Effective income tax rate	12.2	%	14.9	%	15.9	%	15.8	%

The effective income tax rate for the three and six months ended July 2, 2023 reflects the tax impact of a non-taxable contingent consideration adjustment recognized in connection with a decrease in the estimated fair value of our contingent consideration liabilities. The effective income tax rate for the six months ended July 2, 2023 reflects an increase in tax expense related to the revaluation of certain U.S. state operating losses and credit carryforwards. The effective income tax rates for all periods reflect a tax benefit from research and development credits and a net-tax benefit related to share-based compensation.


Segment net revenues
	Three Months Ended					Six Months Ended
	July 2, 2023		June 26, 2022		% Increase/(Decrease)	July 2, 2023		June 26, 2022		% Increase/ (Decrease)



Americas	$	424.7	$	412.7	2.9	$	836.5	$	790.7	5.8
EMEA	147.8		145.2		1.8	291.2		282.1		3.2
Asia	86.7		76.6		13.1	165.4		145.8		13.5
OEM	84.1		70.0		20.2	161.1		127.7		26.2

Segment net revenues	$	743.3	$	704.5	5.5	$	1,454.2	$	1,346.3	8.0

Segment operating profit
	Three Months Ended					Six Months Ended
	July 2, 2023		June 26, 2022		% Increase/(Decrease)	July 2, 2023		June 26, 2022		% Increase/ (Decrease)



Americas	$	116.3	$	114.5	1.6	$	214.9	$	211.4	1.7
EMEA	13.1		12.7		2.9	25.9		21.8		18.6
Asia	23.1		21.5		7.7	44.1		38.9		13.5
OEM	23.8		17.8		33.3	43.8		28.8		52.4

Segment operating profit (1)	$	176.3	$	166.5	5.9	$	328.7	$	300.9	9.3

(1)See Note 13 to our condensed consolidated financial statements included in this report for a reconciliation of segment operating profit to our condensed consolidated income from continuing operations before interest and taxes.

Comparison of the three and six months ended July 2, 2023 and June 26, 2022

Americas

Americas net revenues for the three months ended July 2, 2023 increased $12.0 million, or 2.9%, compared to the prior year period, which was primarily attributable to a $45.3 million increase in sales of new products and price increases and, to a lesser extent, net revenues generated by Standard Bariatrics. The increase in net revenues was partially offset by a $45.1 million decrease in sales volume of existing products.

Americas net revenues for the six months ended July 2, 2023 increased $45.8 million, or 5.8%, compared to the prior year period, which was primarily attributable to a $100.0 million increase in sales of new products, price increases and, to a lesser extent, net revenues generated by Standard Bariatrics. The increase in net revenues was

partially offset by a $74.2 million decrease in sales volume of existing products, notwithstanding the impact of a five-day increase in the number of shipping days during the six months ended July 2, 2023.

Americas operating profit for the three months ended July 2, 2023 increased $1.8 million, or 1.6%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from price increases and a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities. The increase in operating profit was partially offset by an increase in sales expenses to support higher sales.

Americas operating profit for the six months ended July 2, 2023 increased $3.5 million, or 1.7%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales and price increases, partially offset by an increase in sales expenses to support higher sales and an increase in research and development expenses across certain of our product portfolios.

EMEA

EMEA net revenues for the three months ended July 2, 2023 increased $2.6 million, or 1.8%, compared to the prior year period, which was primarily attributable to price increases, favorable fluctuations in foreign currency exchange rates and, to a lesser extent, an increase in sales of new products, partially offset by a $3.2 million decrease in sales volume of existing products.

EMEA net revenues for the six months ended July 2, 2023 increased $9.1 million, or 3.2%, compared to the prior year period, which was primarily attributable to a $7.0 million increase in sales volume of existing products reflecting, in part, the impact of an increase in the number of shipping days, and price increases and, to a lesser extent, an increase in sales of new products. The increase in net revenues was partially offset by $5.5 million of unfavorable fluctuations in foreign currency exchange rates.

EMEA operating profit for the three months ended July 2, 2023 increased $0.4 million, or 2.9%, compared to the prior year period, which was primarily attributable to favorable fluctuations in foreign currency exchange rates and lower expenses related to the European Union Medical Device Regulation within research and development expenses, partially offset by a decrease in gross profit due to higher manufacturing costs resulting from continued cost inflation.

EMEA operating profit for the six months ended July 2, 2023 increased $4.1 million, or 18.6%, compared to the prior year period, which was primarily attributable to lower expenses related to the European Union Medical Device Regulation within research and development expenses and favorable fluctuations in foreign currency exchange rates.

Asia

Asia net revenues for the three months ended July 2, 2023 increased $10.1 million, or 13.1%, compared to the prior year period, which was primarily attributable to a $9.2 million increase in sales volume of existing products, an increase in sales of new products and, to a lesser extent, price increases, partially offset by $3.8 million of unfavorable fluctuations in foreign currency exchange rates.

Asia net revenues for the six months ended July 2, 2023 increased $19.6 million, or 13.5%, compared to the prior year period, which was primarily attributable to a $16.3 million increase in sales volume of existing products and a $9.5 million increase in sales of new products, partially offset by $8.9 million of unfavorable fluctuations in foreign currency exchange rates.

Asia operating profit for the three months ended July 2, 2023 increased $1.6 million, or 7.7%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales, partially offset by unfavorable fluctuations in foreign currency exchange rates and an increase in sales expenses to support higher sales.

Asia operating profit for the six months ended July 2, 2023 increased $5.2 million, or 13.5%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales, partially offset by unfavorable fluctuations in foreign currency exchange rates and an increase in sales expenses to support higher sales.

OEM

OEM net revenues for the three months ended July 2, 2023 increased $14.1 million, or 20.2%, compared to the prior year period, which was primarily attributable to a $7.7 million increase in sales volume of existing products and price increases.

OEM net revenues for the six months ended July 2, 2023 increased $33.4 million, or 26.2%, compared to the prior year period, which was primarily attributable to a $22.7 million increase in sales volume of existing products and price increases.

OEM operating profit for the three and six months ended July 2, 2023 increased $6.0 million, or 33.3%, and $15.0 million, or 52.4%, respectively, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from price increases and higher sales, partially offset by higher research and development expenses and sales expenses.

Liquidity and Capital Resources

We believe our cash flow from operations, available cash and cash equivalents and borrowings under our revolving credit facility will enable us to fund our operating requirements, capital expenditures and debt obligations for the next 12 months and the foreseeable future. We have net cash provided by United States based operating activities as well as non-United States sources of cash available to help fund our debt service requirements in the United States. We manage our worldwide cash requirements by monitoring the funds available among our subsidiaries and determining the extent to which we can access those funds on a cost effective basis.

Cash Flows

Net cash provided by operating activities from continuing operations was $170.6 million for the six months ended July 2, 2023 as compared to $101.9 million for the six months ended June 26, 2022. The $68.7 million increase was primarily attributable to lower tax payments and favorable changes in working capital. The favorable changes in working capital were primarily driven by higher accounts receivable collections compared to the prior year, partially offset by a decrease in accounts payable and accrued expenses from higher payments related to restructuring plans.

Net cash used in investing activities from continuing operations was $29.2 million for the six months ended July 2, 2023, and primarily consisted of capital expenditures of $39.4 million, partially offset by net interest proceeds on swaps designated as net investment hedges of $10.3 million.

Net cash used in financing activities from continuing operations was $186.0 million for the six months ended July 2, 2023, and primarily consisted of a $154.5 million reduction in borrowings and $31.9 million in dividend payments.

In anticipation of the expected completion of the Palette acquisition, we drew $600 million in additional borrowings under our revolving credit facility in July 2023.

Borrowings

The indentures governing our 4.625% Senior Notes due 2027 (the “2027 Notes”) and 4.25% Senior Notes due 2028 (the "2028 Notes") contain covenants that, among other things and subject to certain exceptions, limit or restrict our ability, and the ability of our subsidiaries, to create liens; consolidate, merge or dispose of certain assets; and enter into sale leaseback transactions. As of July 2, 2023, we were in compliance with these requirements.

The obligations under our senior credit agreement (the "Credit Agreement"), the 2027 Notes and 2028 Notes are guaranteed (subject to certain exceptions) by substantially all of our material domestic subsidiaries, and the obligations under the Credit Agreement are (subject to certain exceptions and limitations) secured by a lien on substantially all of the assets owned by us and each guarantor.

Summarized Financial Information – Obligor Group

The 2027 Notes are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes is guaranteed, jointly and severally, by an enumerated group of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. Summarized financial information for the Parent and

Guarantor Subsidiaries (collectively, the “Obligor Group”) as of July 2, 2023 and December 31, 2022 and for the six months ended July 2, 2023 is as follows:


	Six Months Ended
	July 2, 2023
	Obligor Group		Intercompany		Obligor Group (excluding Intercompany)
Net revenue	$	1,074.4	$	154.2	$	920.2
Cost of goods sold	693.6		238.6		455.0
Gross profit	380.8		(84.4)		465.2
Income from continuing operations	103.0		45.1		57.9
Net income	102.4		45.1		57.3



	July 2, 2023						December 31, 2022
	Obligor Group		Intercompany		Obligor Group (excluding Intercompany)		Obligor Group		Intercompany		Obligor Group (excluding Intercompany)

Total current assets	$	942.1	$	182.9	$	759.2	$	878.3	$	110.5	$	767.8
Total assets	3,413.3		1,583.5		1,829.8		3,420.3		1,510.9		1,909.4
Total current liabilities	997.6		773.5		224.1		882.9		627.9		255.0
Total liabilities	3,106.2		879.1		2,227.1		3,168.0		712.3		2,455.7

The same accounting policies as described in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 are used by the Parent Company and each of its subsidiaries in connection with the summarized financial information presented above. The Intercompany column in the table above represents transactions between and among the Obligor Group and non-guarantor subsidiaries (i.e. those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes). Obligor investments in non-guarantor subsidiaries and any related activity are excluded from the financial information presented above.

Critical Accounting Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

In our Annual Report on Form 10-K for the year ended December 31, 2022, we provided disclosure regarding our critical accounting estimates, which are reflective of significant judgments and uncertainties, are important to the presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions and conditions.

New Accounting Standards

See Note 2 to the condensed consolidated financial statements included in this report for a discussion of recently issued accounting guidance, including estimated effects, if any, of adoption of the guidance on our financial statements.

Forward-Looking Statements

All statements made in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; the impact of inflation and disruptions

in our global supply chain on us and our suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of resins and other raw materials, as well as certain components, used in the production or sterilization of our products, transportation constraints and delays, product shortages, energy shortages or increased energy costs, labor shortages in the United States and elsewhere, and increased operating and labor costs; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; our inability to effectively execute our restructuring programs; our inability to realize anticipated savings resulting from restructuring plans and programs; the impact of enacted healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues, and international conflicts and hostilities, such as the ongoing conflict between Russia and Ukraine; public health epidemics including the novel coronavirus (referred to as COVID-19); difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to our business, see Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2022. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to the information set forth in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

(b) Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of July 2, 2023 and December 31, 2022, we had accrued liabilities of approximately $0.6 million and $0.5 million, respectively, in connection with these matters, representing our best estimate of the cost within the range of estimated possible loss that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding lawsuits or claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity.

Item 1A. Risk Factors

See the information set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no significant changes in risk factors for the quarter ended July 2, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

10b5-1 Plan

On May 9, 2023, Cameron Hicks, our Corporate Vice President and Chief Human Resources Officer, adopted a trading plan for the sale of shares of our common stock, which plan is intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) (a “10b5-1 Plan”) under the Securities Exchange Act of 1934, as amended. The 10b5-1 Plan provides for the sale in the open market of up to 3,001 shares of our common stock issuable to Mr. Hicks upon the exercise of stock options with expiration dates within the next two years. The 10b5-1 Plan calls for the sales to be completed during a period beginning on August 8, 2023 and ending on May 9, 2024.

Certificate of Incorporation

At our 2023 Annual Meeting of Stockholders held on May 5, 2023 (the “2023 Annual Meeting”), our stockholders approved, among other things, a proposal to eliminate the supermajority voting provisions from our certificate of incorporation (the “Supermajority Elimination Amendment”). The proposal is described more fully in our definitive proxy statement for the 2023 Annual Meeting, filed with the SEC on March 31, 2023, and the voting results from the meeting are set forth in our Current Report on Form 8-K filed with the SEC on May 11, 2023. The record date established for the 2023 Annual Meeting was March 3, 2023, which exceeded by one business day the maximum of 60 days by which a record date is permitted to precede a meeting of stockholders under the Delaware General Corporation Law (the “DGCL”) and our Amended and Restated Bylaws. We intend to seek the approval of the Delaware Court of Chancery, pursuant to Section 205 of the DGCL, to validate and declare effective the approval of the Supermajority Elimination Amendment, as well as the other matters considered and approved by our stockholders at the 2023 Annual Meeting. We will provide further information regarding this process as the proceeding under Section 205 moves forward.

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this report:


Exhibit No.		Description

31.1	—	Certification of Chief Executive Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
31.2	—	Certification of Chief Financial Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
32.1	—	Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	—	Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1	—	The following materials from our Quarterly Report on Form 10-Q for the quarter ended July 2, 2023, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Cover Page; (ii) the Condensed Consolidated Statements of Income for the three and six months ended July 2, 2023 and June 26, 2022; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 2, 2023 and June 26, 2022; (iv) the Condensed Consolidated Balance Sheets as of July 2, 2023 and December 31, 2022; (v) the Condensed Consolidated Statements of Cash Flows for the six months ended July 2, 2023 and June 26, 2022; (vi) the Condensed Consolidated Statements of Changes in Equity for the three and six months ended July 2, 2023 and June 26, 2022; and (vii) Notes to Condensed Consolidated Financial Statements.
104.1	—	The cover page of the Company's Quarterly Report on Form 10-Q for the quarter ended July 2, 2023, formatted in inline XBRL (included in Exhibit 101.1).

____________________________________

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TELEFLEX INCORPORATED

By:

/s/ Liam J. Kelly

Liam J. Kelly

President and Chief Executive Officer

(Principal Executive Officer)

By:

/s/ Thomas E. Powell

Thomas E. Powell

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

Dated: August 3, 2023